|Host entity||:||Faculty of Pharmacy, Universitas Pancasila|
|Time Requirement||:||Three days a week (60%)|
|Language Skills||:||Indonesian and English|
|Start date||:||1 May 2021|
|Deadline||:||9 April 2021|
Protecting society from poor quality medicines is a formidable task for national medicine regulatory authorities, especially in a resource-limited setting such as in Indonesia. Although post-market surveillance is a routine activity for medicine regulators, each country has different method in performing this task. To date, there are no globally recognised methods for estimating the prevalence of substandard and falsified medicines in a country, or for assessing their impact on health or the economy. With support from the UK government’s National Institute for Health Research, the Faculty of Pharmacy at Universitas Pancasila (UP) will collaborate with Imperial College London and Erasmus School of Health Policy and Management (ESHPM) to pilot a sentinel surveillance system for medicine quality, and to develop methods for estimating the prevalence, health and economic impact of poor quality medicines.
The concept arose from earlier research into the factors that incentivise the production, trade or consumption of falsified or substandard medicines. Substandard and falsified medicines are not distributed evenly throughout the market. Instead, they cluster around specific risk factors, which differ for substandard and for falsified medicines. Examples of risks for substandard medicines include irrationally low price, or poor product stability combined with long distribution chain. Examples of risks for falsified medicines include demand for off-label use, or availability in the unregulated supply chain..
We plan to conduct sentinel surveillance for substandard and falsified medicines in a number of areas, and then use the resulting data as the basis for developing national estimates of the risk of substandard and falsified medicines nationwide. (The process is modelled on a similar process used to develop methods for the estimation of populations at risk for HIV, pioneered in Indonesia in 2002 and subsequently adopted as a global gold standard by the World Health Organisation.)
Sentinel surveillance will be conducted in up to 9 districts within 5 provinces in Indonesia. The sample collection will be conducted in collaboration and with guidance from Balai Besar POM (BBPOM), and/or Badan Pusat Statistik (BPS), and in close coordination with the local Dinas Kesehatan. The process will involve mystery shoppers who will visit selected health care facilities and pharmacies for high risk medicines purchasing.
The medicines obtained will then transported to Jakarta for a complete compendial test according to Indonesian Pharmacopeia standards (FI) or the United States Pharmacopeia (USP). The complete compendial test comprises of testing for solid preparations, testing for semi-solid and non-sterile liquid preparations, testing for contamination, testing for sterile products, determining levels of active substances, determining potential for antibiotics (note: if there are antibiotics among the tested products), identification of active substance type, and degradation testing. The identification of assay and type of active substance will be conducted using spectrophotometric method or other relevant method. To that end, we seek to involve a laboratory manager to supervise and manage the laboratory testing process throughout this study to support the estimation of prevalence of substandard and falsified medicines.
The selected candidate is expected to provide the following work:
For interested candidates, please send your CV (with two names of referee and their phone number)
and cover letter to: email@example.com, cc: firstname.lastname@example.org no later than 9 April 2021.
Share this :